# Eleftherios P. Mamounas

Source: https://onco.cc/people/eleftherios-mamounas/  
OnCo record `eleftherios-mamounas` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Surgeon who chairs the NRG Oncology breast committee and co-led the KATHERINE and B-42 trials.

## Summary

Eleftherios Mamounas (Orlando Health) chairs the NRG Oncology Breast Committee and was NSABP protocol chair for B-42 (extended letrozole) and co-chair of KATHERINE, which established adjuvant T-DM1 for residual disease after neoadjuvant therapy. He has led work using the 21-gene assay to predict locoregional recurrence and radiotherapy benefit. His current trials test omission of surgery and radiotherapy after excellent neoadjuvant response.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: breast; surgery; nrg-oncology
- Role: Medical Director, Comprehensive Breast Program, Orlando Health Cancer Institute; Chair, NRG Oncology Breast Committee
- Specialisms: Breast surgical oncology; Adjuvant and neoadjuvant trials; Genomic risk assays; Cooperative-group leadership

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Mamounas%20EP%5BAuthor%5D%20breast%20NSABP

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/)
- institutions: [Orlando Health Cancer Institute](https://onco.cc/institutions/orlando-health-cancer-institute/)
- trials: [KATHERINE](https://onco.cc/trials/katherine/)
- key papers: [KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment](https://onco.cc/key-papers/paper-katherine-nejm-2019/)

---
JSON: https://onco.cc/api/v1/entities/eleftherios-mamounas.json